AChE/BChE-IN-35

AChE/BChE-IN-35 (Compound L3) (5 min) inhibits eeAChE, hAChE, and eqBChE with IC₅₀ values of 123.66 nM, 122.34 nM, and 488.00 nM, respectively^[1].
AChE/BChE-IN-35 (50-100 μM; 24 h) shows low cytotoxicity toward bEnd.3 cells, with viability remaining close to 80% after 24 h treatment at 100 μM^[1].
AChE/BChE-IN-35 (5 μg/mL; 30-300 min) crosses an in vitro bEnd.3 cell blood-brain barrier model with an apparent permeability coefficient of 11.25 × 10^-6 cm/s^[1].
AChE/BChE-IN-35 (4 h) is transported into U87 cells via LAT1, as shown by undetectable intracellular levels in the presence of an LAT1 competitive inhibitor^[1].
AChE/BChE-IN-35 (10-50 μM; 24 h) shows low cytotoxicity toward HBMEC, BV2, PC-12, SH-SY5Y, with viability remaining above 50% at tested concentrations after 24 h treatment^[1].
AChE/BChE-IN-35 (10-100 μM; 24 h) shows low hepatotoxicity in HepG2 and L02 cells, with viability remaining above 50% at tested concentrations after 24 h treatment[^1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.